Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Relistor Expansion Plans In Question Following “Complete Response” Letter

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

FDA requested more clinical data on Salix/Progenics’ sNDA for approval of the subcutaneous formulation of methylnaltrexone in chronic, non-cancer pain patients with opioid-induced constipation. The regulatory setback could have implications for the companies’ planned September filing of an oral formulation in the same patient population.

You may also be interested in...



Progenics Finds New Partner For Relistor In Salix

A casualty of the Pfizer/Wyeth merger, Relistor rights bring Progenics $60 million upfront plus up to $290 million in milestones plus royalties.

Wyeth/Progenics’ Relistor: FDA Says Yes, EU Likes It, Too

Compound helps bowel function in dying patients on opioids.

Biosimilars: US FDA Considering ‘Guardrails’ To Prevent Misinformation

Agency wants to ensure patients ‘aren’t unnecessarily or unfairly scared off or intimidated’ from taking biosimilars, Office of Therapeutic Biologics and Biosimilars' acting policy director Eva Temkin tells the FDA/CMS Summit; Temkin says recent guidance on biosimilar insulins shows agency is trying to be flexible on interchangeability data requirements.


Topics

Related Companies

UsernamePublicRestriction

Register

PS005211

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel